Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantationAmerican Journal of Hematology.  96:E396-E398. 2021
2019 Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost ImplicationsBiology of Blood and Marrow Transplantation.  25:233-238. 2019
2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantBone Marrow Transplantation.  53:1345-1348. 2018
2018 Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple MyelomaBiology of Blood and Marrow Transplantation.  24:1379-1385. 2018
2017 Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaBiology of Blood and Marrow Transplantation.  23:269-277. 2017
2017 Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failureBone Marrow Transplantation.  52:157-158. 2017
2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresCancer Causes and Control.  27:81-91. 2016
2015 Telomere length in hematopoietic stem cell transplantation for severe aplastic anemia is it ready for "prime time"? 2015
2015 Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia 2015

Chapter

Year Title Altmetric
2019 Sources of cells for hematopoietic cell transplantation.  73-84. 2019

Investigator On

  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY
  • International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation  awarded by International Myeloma Foundation
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS
  • Multi-center, Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) Regimen  awarded by University of Michigan
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC.
  • Private Grant  awarded by ASTELLAS PHARMA US, INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by ARRAY BIOPHARMA
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC.
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by MUNDIPHARMA
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC.
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program
  • The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma  awarded by National Cancer Institute/NIH/DHHS
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center
  • Education And Training

  • Atlanta Medical Center, Internship
  • Atlanta Medical Center, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • University of Virginia Hospital, Postdoctoral Fellowship
  • Doctor of Medicine in Internal Medicine Residency Program, Medical College of Georgia 1998
  • Full Name

  • Racquel Innis-Shelton